Prelude Therapeutics

Historical price data

Prelude Therapeutics is a publicly traded, clinical-stage biotech focused on discovering and developing targeted cancer therapies. The company has built a diverse pipeline of 11 candidates, with key programs including a selective SMARCA2 degrader (PRT3789) for SMARCA4-mutant cancers and a CDK9 inhibitor (PRT2527) for hematologic and solid tumors. Its strategy centers on applying novel mechanisms like targeted protein degradation to clinically validated targets to create differentiated, precision medicines. Prelude operates with an integrated R&D team aiming to translate scientific insights into transformative treatments for patients.

A flexible, biology-driven discovery engine that is not constrained by a single platform or modality. It focuses on applying novel mechanisms like targeted protein degradation and mutant-selective inhibition to clinically validated cancer targets.

Prelude competes in nuanced segments of precision oncology, facing rivals in SMARCA2 degradation (e.g., Foghorn), CDK9 inhibition (e.g., Astex), and JAK2 inhibition (e.g., Incyte). Its differentiation strategy relies on novel modalities (degraders) and high selectivity (mutant-specific inhibitors) to potentially achieve superior efficacy and safety versus established approaches.